Report: New Cannabinoid Drug Interactions

Posted on by American Academy of Cannabinoid Medicine (AACM)
Picture taken on January 15, 2012 in Lille, northern France, of drug capsules. AFP PHOTO PHILIPPE HUGUEN (Photo credit should read PHILIPPE HUGUEN/AFP/Getty Images) Adrian Devitt-Lee of Project CBD writes: "The interactions between plant cannabinoids and a drug-metabolizing enzyme called carboxylesterase 1 (CES1) was recently published in Drug Metabolism and Distribution. Researchers at the Universities of Michigan and Florida showed that THC, CBD, and cannabinol (CBN) all inhibit CES1. CES1 is important for activating or inactivating drugs that regulate blood pressure, as well as the ...
More

Commentary: This is Your “Little Brain” on Cannabis

Posted on by David G Ostrow, MD, PhD, LFAPA
This article from Psychology Today brings up an important topic of conversation for medical professionals. Perhaps the high concentration of CB1 receptors in the cerebellum is a protective adaptation. Poor coordination and difficulty with visual tracking should be a warning to slow down, both in terms of cannabinoid ingestion and movement. Unfortunately, poor judgement on the part of the frontal cortex and reward circuitry is able to override this primitive early warning system and we all know the outcome when that happens. Continuing to ignore the brain’s innate warning circuitry would b...
More

Study: Cannabis in Oncology Practice

Posted on by American Academy of Cannabinoid Medicine (AACM)
Image: Royal Queen Seeds Promoting MMJ Among Oncologist in the USA By John Taenzler, Ph.D. for Cannabis Business Executive In October 2018, a survey was conducted among 87 oncologists (ONCs) in 19 of the States where medical marijuana (MMJ) has been approved and available.  An objective of this research was to assess the depth of knowledge about cannabis pharmacology, state-specific regulations, and attitudes of national medical organizations toward MMJ. In examining and assessing the perceptions and attitudes of these ONCs towards MMJ, physicians were asked about their curre...
More

Protections Needed for Cannabis Users on Their Own Time, Based on Science

Posted on by Dr. Michael Milburn
I wrote the following in support of two bills in the Oregon State Legislature that would protect cannabis patients and adults who use legally off-the-job from losing employment due to a failed drug test. As all cannabinoid medicine specialists know, presence of THC in the blood, saliva or urine does not equal impairment. Allowing the termination of an employee because they used a legal substance on their own time should be viewed as a fundamental violation of a citizen’s rights.  If an employee is using a disabling substance at work (e.g., alcohol, cannabis) and is impaired, it should...
More

A Brief History of Medical Cannabis and Cannabinoids in the U.S.

Posted on by davidbearman
The Ayurvedic Medicine Materia Medica Since the late 1940s and early 1950s, both state and federal entities have assiduously avoided treating cannabis as the medicine it has been for over 4,000 years. Cannabis has been recognized as a medicine since at least 2637 B.C.E. when it was included in the first known pharmacopoeia, the Ping Ts’ao Ching, alleged to be written by the second Emperor of China, Shen Neng. Cannabis has appeared in all subsequent major pharmacopoeias including an Ayurvedic Medicine Materia Medica, dated from between 1100 B.C.E. and 1700 B.C.E., as well as the Ebers Papy...
More

Older Adults Tolerate Medical Marijuana Well

Posted on by David G Ostrow, MD, PhD, LFAPA
From: Grandmas Smoking Weed The following article is an excellent example of the value of community-based and patient-centered observational study in developing a better understanding of the therapeutic usefulness of cannabinoid-based medicine for specific conditions, in this case chronic pain and opioid analgesic dependence. The fact that it was carried out through chart review in a clinic seeing mostly older adults is all the more encouraging, as the efficacy and tolerability of THC-containing cannabis medicines among the elderly might be expected to be lower than among younger populatio...
More

NORML: Cannabis Exposure Not Associated With Significant Changes In Brain Morphology

Posted on by National Organization for the Reform of Marijuana Laws (NORML) Offield
For Immediate Release Contact: Paul ArmentanoNORML Deputy Director Paul@norml.org Cannabis exposure is not associated with significant changes in brain morphology in either older or younger subjects, according to a pair of newly published studies. Commenting on the two studies, NORML Deputy Director Paul Armentano said: “These findings dispute the long-standing ‘stoner-stupid’ stereotype and should help to assuage fears that cannabis’ acute effects on neurocognitive behavior may persist long after drug ingestion, or that cannabis exposure is associated with any sort of signifi...
More

Study: Review of CBD for treatment-resistant epilepsy

Posted on by Lauren Offield
This recent clinical trial concerning cannabidiol (CBD) and seizure disorders demonstrated that “CBD might reduce seizure frequency and an adequate safety profile in children and young adults with highly treatment-resistant epilepsy.” In 2016, doctors across the United States began an open-label interventional trial focused on patients (aged 1–30 years) with severe, intractable, childhood-onset, treatment-resistant epilepsy. These patients were all receiving stable doses of anti-epileptic medications prior to study entry and were enrolled in an expanded-access program at 11 epilepsy cente...
More

Study: Marijuana Dependence

Posted on by Lauren Offield
According to Dr. David Bearman, cannabis is "one of the safest therapeutic agents known to man, even safer than eating ten potatoes." This was further supported by Dr. Jack E. Henningfield and Dr. Neal L. Benowitz, two well-known addictionologists located at the National Institute on Drug Abuse and University of California at San Francisco, respectively. Both physicians concluded that cannabis is less dangerous than caffeine. This was determined by ranking five psychoactive substances on the following five criteria: withdrawal, reinforcement, tolerance, dependence, and intoxication. Further, ...
More

Commentary: Endorsing Cannabis as an Opioid Substitute ‘Irresponsible’

Posted on by David G Ostrow, MD, PhD, LFAPA
This is yet another piece of propaganda in the counter-attack by Big Pharma/FDA/DEA on our progress. So sad, so stereotypical and so mistaken. I am really embarrassed by this endless repetition of falsehoods and circular reasoning. I think we have to call it for what it is, push forward the recent World Health Organization recommendations for rescheduling to lowest category possible, which would facilitate better research on safer alternatives that could end this epidemic. Anything else is what is irresponsible. -Dr. David Ostrow Endorsing Cannabis as an Opioid Substitute 'Irresponsibl...
More